Philips Medical Systems and North American Scientific subsidiary Theseus Imaging are collaborating to research and develop improved methodology for noninvasive imaging of cardiac cell death. The research will focus on optimizing techniques and instrumentation for use with Theseus' Apomate work-in-progress in vivo nuclear medicine imaging agent, according to the vendor.
Apomate targets cells undergoing apoptosis or necrosis, according to the firms. Under the terms of the relationship, Theseus will provide images and other data from Apomate cardiac imaging trials to Bothell, WA-based Philips. Philips will then apply its Vantage Pro attenuation correction technology to develop improved fusion of Apomate and thallium images.
By AuntMinnie.com staff writersFebruary 21, 2002
Related Reading
NAS moves into the black, February 20, 2002
Acquisitions boost Philips Medical results, February 11, 2002
NAS revenues grow while income dips, December 11, 2001
Philips sets sales target for medical division, December 5, 2001
NAS unit begins clinical Apomate trials, November 30, 2001
Copyright © 2002 AuntMinnie.com
